Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer

• Published in: Scientific reports Vol. 9; no. 1; pp. 16761 - 8
• Main Authors: Matsumoto, Teppei, Hatakeyama, Shingo, Yoneyama, Tohru, Tobisawa, Yuki, Ishibashi, Yusuke, Yamamoto, Hayato, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Ito, Hiroyuki, Nishimura, Shin-Ichiro, Ohyama, Chikara
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.11.2019; Nature Publishing Group
• Subjects: 631/45/221; 631/67/589/466; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Biomarkers, Tumor - blood; Case-Control Studies; Castration; Discriminant Analysis; Glycoproteins; Humanities and Social Sciences; Humans; Hyperplasia; Immunoglobulins; Male; Middle Aged; multidisciplinary; N-glycans; Polysaccharides; Polysaccharides - blood; Prognosis; Prostate cancer; Prostatic Hyperplasia - metabolism; Prostatic Neoplasms, Castration-Resistant - diagnosis; Prostatic Neoplasms, Castration-Resistant - metabolism; Retrospective Studies; Science; Science (multidisciplinary); Sensitivity and Specificity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-53384-y

We investigated the diagnostic and prognostic potential of serum N -glycan profiling for castration-resistant prostate cancer (CRPC). We retrospectively investigated serum N -glycan structural analysis by glycoblotting for 287 patients with benign prostatic hyperplasia (BPH), 289 patients with newly diagnosed prostate cancer (PC), 57 patients with PC treated with androgen-deprivation therapy without disease progression (PC-ADT), and 60 patients with CRPC. N -Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N -glycan score) by discriminant analysis based on the combination of 9 N -glycans that were significantly associated with CRPC. The median CRPC N -glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The CRPC N -glycan score could classify CRPC patients with sensitivity, specificity, and area under the curve of 87%, 69%, and 0.88, respectively. The CRPC N -glycan score >1.7 points was significantly associated with poor prognosis in patients with CRPC. The glycoprotein analysis showed that not immunoglobulins but α-1-acid glycoprotein (AGP) were a potential candidate for the carrier protein of N -glycans. The overexpression of specific N -glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC.